[1]郭珊岚,张 琳,周 洁,等.神经内分泌肿瘤组织中SSTR2、dMMR、VEGF表达与临床病理学特征及预后的相关性研究[J].现代检验医学杂志,2026,41(02):111-116.[doi:10.3969/j.issn.1671-7414.2026.02.019]
　GUO Shanlan,ZHANG Lin,ZHOU Jie,et al.Correlation between the Expression of SSTR2, dMMR, and VEGF in Neuroendocrine Neoplasms Tissues and Clinicopathological Characteristics and Prognosis[J].Journal of Modern Laboratory Medicine,2026,41(02):111-116.[doi:10.3969/j.issn.1671-7414.2026.02.019]
点击复制

神经内分泌肿瘤组织中SSTR2、dMMR、VEGF表达与临床病理学特征及预后的相关性研究()

《现代检验医学杂志》[ISSN:/CN:]

卷:
第41卷
期数:
2026年02期
页码:
111-116
栏目:
论著
出版日期:
2026-03-15

文章信息/Info

Title:
Correlation between the Expression of SSTR2, dMMR, and VEGF in Neuroendocrine Neoplasms Tissues and Clinicopathological Characteristics and Prognosis
文章编号:
1671-7414（2026）02-111-06
作者:
郭珊岚，张 琳，周 洁，李 静
资阳市中心医院病理科；四川资阳 641300
Author(s):
GUO Shanlan，ZHANG Lin，ZHOU Jie，LI Jing
Department of Pathology, Ziyang Central Hospital, Sichuan Ziyang 641300, China
关键词:
神经内分泌肿瘤; 生长抑素受体2; 错配修复缺陷; 血管内皮生长因子
分类号:
R730.2；R730.43
DOI:
10.3969/j.issn.1671-7414.2026.02.019
文献标志码:
A
摘要:
目的?探究神经内分泌肿瘤(NENs)患者组织中生长抑素受体2(SSTR2)、错配修复缺陷(dMMR)、血管内皮生长因子(VEGF)与临床病理学特征及预后的相关性。方法?选取2020年1月~2022年10月在资阳市中心医院确诊的108例NENs患者,均进行NENs肿瘤组织病理活检,采用免疫组织化学法检测SSTR2、dMMR、VEGF表达情况,根据随访两年的预后分为生存组(n=83)与死亡组(n=25)。比较两组基线资料和NENs肿瘤组织SSTR2、dMMR、VEGF表达情况,采用Spearman相关性分析SSTR2、dMMR、VEGF表达与临床病理学特征的关系,Logistic回归分析NENs患者预后的影响因素,绘制受试者操作特征(ROC)曲线分析SSTR2、dMMR、VEGF对NENs患者预后的预测价值。结果两组肿瘤直径、病理分级、浸润深度比较差异具有统计学意义(U=2.323、2.751、2.433,均P<0.05);死亡组SSTR2、VEGF阳性表达率低于生存组(36.00%vs78.31%、44.00%vs84.34%),dMMR表达率高于生存组(72.00%vs33.73%),差异具有统计学意义(χ2=15.947、16.673、11.505,均P<0.001);Spearman相关性分析,SSTR2、VEGF与NENs肿瘤直径、浸润深度、病理分级呈负相关(rSSTR2=-0.403、-0.527、-0.558,rVEGF=-0.441、-0.514、-0.537,均P<0.05),dMMR与NENs肿瘤直径、浸润深度、病理分级呈正相关(r=0.428、0.539、0.571,均P<0.05)。COX回归分析,在校正其他因素前后,SSTR2阳性、VEGF阳性是NENs患者预后的独立保护因素,dMMR表达是NENs患者预后的独立危险因素(均P<0.001);ROC曲线分析,SSTR2阴性、VEGF阴性、dMMR表达预测NENs患者预后的曲线下面积(AUC)分别为0.712、0.702、0.691;三者联合预测NENs患者预后的AUC为0.880,预测价值明显优于三者单独预测,差异具有统计学意义(Z=3.065、3.482、3.155,均P<0.01)。结论SSTR2、dMMR、VEGF与NENs患者肿瘤直径、浸润深度、病理分级等临床病理学特征显著相关,是预后的独立影响因素,且联合预测预后的价值可靠。
Abstract:
Objective To investigate the correlation between somatostatin receptor 2 (SSTR2), mismatch repair deficient (dMMR), vascular endothelial growth factor (VEGF), and clinicopathological characteristics and prognosis in patients with neuroendocrine neoplasms (NENs). Methods A total of 108 patients with NENs diagnosed at Ziyang Central Hospital between January 2020 and October 2022 underwent histopathological biopsy of NENs tumor tissue were selected. Immunohistochemical method was used to detect the expression of SSTR2, dMMR, and VEGF. Based on a 2-year follow-up, patients were categorized into a survival group (n=83) and a mortality group (n=25). The baseline characteristics and the expression of SSTR2, dMMR, and VEGF in NENs tu-mor tissue were compared between the two groups. Spearman correlation analysis was used to assess the relationship between the expression of SSTR2, dMMR, and VEGF and clinicopathological features. Logistic regression analysis was conducted to identify factors influencing the prognosis of NENs patients. Receiver operating characteristic (ROC) curves were plotted to evaluate the predictive value of SSTR2, dMMR, and VEGF for predicting the prognosis of NENs patients. Results There were significant differences in tumor diameter, pathological grading, and depth of invasion between the two groups (U=2.323, 2.751, 2.433, all P<0.05). In the mortality group, the positive expression rates of SSTR2 and VEGF were 36.00% and 44.00%, respectively, low-er than those in the survival group (78.31% and 84.34%, respectively). The expression rate of dMMR was 72.00%, which was higher than that in the survival group (33.73%) (χ2=15.947, 16.673, 11.505, all P<0.001). Spearman correlation analysis showed that SSTR2 (r=-0.403, -0.527, -0.558), VEGF (r=-0.441, -0.514, -0.537) were negatively correlated with tumor diameter,depth of invasion, and pathological grading of NENs, while dMMR (r=0.428, 0.539, 0.571) was positively correlated with tumor diameter, depth of invasion, and pathological grading of NENs (all P<0.05). COX regression analysis showed that before and af-ter adjusting for other factors, SSTR2 positivity and VEGF positivity were independent protective factors for the prognosis of NENs patients, while dMMR expression, was an independent risk factor for the prognosis of NENs patients (all P<0.001). ROC curve analysis showed that SSTR2 negativity, VEGF negativity, and dMMR expression predicted NENs prognosis with area un-der the curve (AUC) values of 0.712, 0.702, and 0.691, respectively. The combined AUC for predicting prognosis using all three factors was 0.880, demonstrating significantly superior predictive value compared to individual factors (Z=3.065, 3.482, 3.155, all P<0.01). Conclusions SSTR2, dMMR, VEGF are significantly correlated with clinicopathological characteristics such as tu-mor diameter, depth of invasion, and pathological grading in NENs patients. They are independent prognostic factors for NEN, and their combined predictive value for prognosis is reliable.

参考文献/References:

[1] RIZEN E N, PHAN A T. Neuroendocrine tumors: a relevant clinical update[J]. Current Oncology Reports, 2022, 24(6): 703-714.
[2] SI Y N, KIM S, OU J F, et al. Anti-SSTR2 anti-body-drug conjugate for neuroendocrine tumor thera-py[J]. Cancer Gene Therapy, 2021, 28(7/8): 799-812.
[3] BARTLEY A N, MILLS A M, KONNICK E, et al. Mis-match repair and microsatellite instability testing for immune checkpoint inhibitor therapy: guideline from the college of American pathologists in collaboration with the association for molecular pathology and fight colorectal cancer[J]. Archives of Pathology & Labora-tory Medicine, 2022, 146(10): 1194-1210.
[4] 彭凤翔,高蓉梅,李永春,等.非小细胞肺癌患者血清铁蛋白表达水平及其对微血管侵犯预测价值研究[J].现代检验医学杂志, 2023, 38(2): 171-175. PENG F X, GAO R M, LI Y C, et al. Study on serum ferritin expression and its predictive value for micro-vascular invasion in patients with non-small cell lung cancer [J]. Journal of Modern Laboratory Medicine, 2023, 38(2): 171-175.
[5] SHAH M H, GOLDNER W S, BENSON A B, et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology [J]. Journal of the National Comprehensive Cancer Net-work , 2021, 19(7): 839-868.
[6] PATEL S A, NILSSON M B, LE X N, et al. Molecular mechanisms and future implications of VEGF/VEGFR in cancer therapy[J]. Clinical Cancer Research, 2023, 29(1): 30-39.
[7] 李璐杰,宋晨宇,周小琦,等.胰腺神经内分泌肿瘤CT征象与SSTR2、VEGFR2及MGMT表达的关系[J].中山大学学报(医学科学版), 2021, 42(6): 892-899. LI L J, SONG C Y, ZHOU X Q, et al. Relationship of CT signs and expression of SSTR2,VEGFR2 and MGMT in Pancreatic neuroendocrine neoplasms[J]. Journal of Sun Yat-sen University (Medical Science Edition), 2021, 42(6): 892-899.
[8] OAKNIN A, GILBERT L, TINKER A V, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or profi-cient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study[J]. Journal for Immunotherapy of Cancer, 2022, 10(1):e003777.
[9] FONTI R, PANICO M, PELLEGRINO S, et al. Hetero-geneity of SSTR2 expression assessed by 68Ga-DOTA-TOC PET/CT using coefficient of variation in patients with neuroendocrine tumors[J]. Journal of Nuclear Medicine, 2022, 63(10): 1509-1514.
[10] QIN S S, YANG Y Y, ZHANG J J, et al. Effective treat-ment of SSTR2-positive small cell lung cancer usin-g211At-containing targeted α-particle therapy agent which promotes endogenous antitumor immune response[J]. Molecular Pharmaceutics, 2023, 20(11): 5543-5553.
[11] 温林春,朱信强.SSTR2和VEGF在胃癌组织中的表达及其意义[J].江苏医药, 2019, 45(3): 249-251, 封3. WEN L C, ZHU X Q. Expressions and significance of SSTR2 and VEGF in gastric carcinoma[J]. Jiangsu Medical Journal, 2019, 45(3): 249-251, F3.
[12] POPA O, TABAN SM, PANTEA S, et al. The new WHO classification of gastrointestinal neuroendocrine tumors and immunohistochemical expression of soma-tostatin receptor 2 and 5 [J]. Experimental and Thera-peutic Medicine, 2021, 22(4): 1179.
[13] ASA S L, METE O, SCH?LLER U, et al. Cauda equi-na neuroendocrine tumors: distinct epithelial neuroen-docrine neoplasms of spinal origin[J]. American Journal of Surgical Pathology, 2023, 47(4): 469-475.
[14] OLAVE M C, GRAHAM R P. Mismatch repair defi-ciency: the what, how and why it is important[J]. Genes Chromosomes & Cancer, 2022, 61(6): 314-321.
[15] MAIO M, ASCIERTO P A, MANZYUK L, et al. Pem-brolizumab in microsatellite instability high or mis-match repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study[J]. Annals of Oncol-ogy, 2022, 33(9): 929-938.
[16] LOU L, LYU F Z, WU X, et al. Clinical implications of mismatch repair deficiency screening in patients with mixed neuroendocrine non-neuroendocrine neoplasms (MiNEN)[J]. European Journal of Surgical Oncology, 2021, 47(2): 323-330.
[17] WESTCOTT P M K, MUYAS F, HAUCK H, et al. Mismatch repair deficiency is not sufficient to elicit tu-mor immunogenicity[J]. Nature Genetics, 2023, 55(10):1686-1695.
[18] NGUYEN T H C, NGUYEN TRAN B S, NGUYEN T P, et al. Deficient mismatch repair proteins in gastric mixed neuroendocrine non-neuroendocrine neoplasm:a rare case report[J]. Case Reports in Oncology, 2023, 16(1): 1172-1182.
[19] MABETA P, STEENKAMP V. The VEGF/VEGFR axis revisited: implications for cancer therapy[J]. Inter-national Journal of Molecular Sciences, 2022, 23(24):15585.
[20] 王锐,吴娜,陈文婷,等.GOLPH3、VEGF在胃癌组织中的表达情况及其临床意义[J].中国实验诊断学,2022,26(9):1265-1268. WANG R, WU N, CHEN W T, et al. Expression of golph3 and VEGF in gastric cancer and its clinical sig-nificance[J]. Chinese Journal of Laboratory Diagnosis, 2022, 26(9): 1265-1268.
[21] MALEKAN M, EBRAHIMZADEH M A. Vascular en-dothelial growth factor receptors [VEGFR] as target in breast cancer treatment: current status in preclinical and clinical studies and future directions[J]. Current Topics in Medicinal Chemistry, 2022, 22(11): 891-920.
[22] CUNY T, DE HERDER W, BARLIER A, et al. Role of the tumor microenvironment in digestive neuroen-docrine tumors [J]. Endocrine-Related Cancer, 2018, 25(11): R519-R544.

备注/Memo

备注/Memo:
基金项目：四川省抗癌协会临床科研（齐鲁）项目编号（XH2022-120）。
作者简介：郭珊岚（1980-），女，本科，副主任医师，研究方向：临床病理，E-mail：18090639070@163.com。
更新日期/Last Update: 2026-03-15